GLP-1 Microdosing: What It Is, Who's Doing It, and Whether the Evidence Supports It

In the forums, the private Facebook groups, and the DMs that arrive in my inbox, a particular conversation keeps surfacing. Women who've reached their goal weight on semaglutide or tirzepatide, who want to stay there without regaining, but who also want to reduce their medication burden. The side effects at 2.4mg are real. The cost is significant. The question they're asking is: what if I just use less?

This is GLP-1 microdosing. It's happening. It's largely undiscussed in clinical settings. And the honest answer about whether it works is more nuanced than either enthusiasts or sceptics tend to acknowledge.

What Microdosing Actually Means in This Context

The term "microdosing" in GLP-1 circles doesn't mean the sub-perceptual doses associated with psychedelics. It means using doses significantly lower than the standard therapeutic range, specifically below the approved maintenance dose, as a long-term maintenance strategy after reaching goal weight.

In practice, this typically means:

• Semaglutide (Wegovy/Ozempic): Maintaining on 0.25mg or 0.5mg weekly rather than titrating to the approved 2.4mg maintenance dose
• Tirzepatide (Mounjaro): Maintaining on 2.5mg or 5mg rather than the 10-15mg doses used for maximum weight loss
• Frequency reduction: Some users also extend their dosing interval, moving from weekly to every 10 or 14 days

The goal is not continued weight loss. The goal is weight maintenance with reduced cost, reduced side effects, and reduced medication exposure.

Who Is Doing This and Why

The population doing this is fairly specific. It tends to be women who:

• Have reached their target weight after a full treatment course
• Want to avoid the rapid regain documented in discontinuation studies (approximately two-thirds of lost weight returns within a year of stopping)
• Find full maintenance doses produce side effects that significantly affect quality of life
• Are managing the cost of private prescribing themselves

The motivation is logical. The STEP 4 discontinuation data is persuasive, and the desire to find a middle path between full-dose continuation and complete cessation is understandable.

What's different about this population compared to standard clinical trial participants is that they're not trying to lose more weight. They want a minimum effective dose for maintenance. Whether that dose is meaningful, useless, or harmful at sub-therapeutic levels is the key empirical question, and the honest answer is we don't yet know.

What the Evidence Says (and Doesn't Say)

There Are No Controlled Trials

This is the central fact. No randomised controlled trial has investigated sub-therapeutic semaglutide or tirzepatide dosing for weight maintenance. The STEP trials and SURMOUNT trials all used protocol-specified dose titration schedules. There is no clinical trial of 0.25mg weekly semaglutide as a maintenance strategy.

The evidence base for microdosing is therefore:

• Case reports and anecdotal accounts (substantial in volume, poor in quality)
• Pharmacological inference from dose-response data
• Mechanistic reasoning about GLP-1 receptor activity at lower concentrations

None of these constitute controlled evidence.

What Pharmacology Suggests

GLP-1 receptor agonists have a well-characterised dose-response relationship. Higher doses produce greater weight loss. Lower doses produce less weight loss but still produce measurable GLP-1 receptor activity. The receptor effects on appetite, gastric emptying, and insulin secretion are present across the dosing range, though attenuated at lower concentrations.

This gives the pharmacological rationale for why microdosing might do something. A 0.25mg weekly dose of semaglutide will still occupy GLP-1 receptors and produce some degree of satiety augmentation. Whether that's sufficient to maintain weight in a specific individual depends on their baseline biology, diet, and activity levels.

What Anecdotal Reports Suggest

From the accounts I've read and the women I've spoken to, the pattern is inconsistent. Some women report that 0.25mg weekly, combined with stable diet and exercise habits established during active treatment, is sufficient to maintain weight without meaningful weight regain over 6-18 months. Others find the sub-therapeutic dose does little and regain begins within weeks.

The variability probably reflects genuine individual differences in GLP-1 receptor sensitivity, the strength of habits established during treatment, and baseline metabolic profile. Without a controlled trial, it's impossible to predict which group any individual woman falls into.

The Risks Worth Knowing

Unstudied Long-Term Safety

The long-term safety data for GLP-1 medications at standard doses is accumulating, but it's not complete. At sub-therapeutic doses maintained indefinitely, there is essentially no safety data. This doesn't mean it's dangerous, but the absence of evidence is not evidence of absence.

Specific concerns that haven't been studied at microdose levels include:

• Thyroid C-cell effects (the reason GLP-1 medications carry contraindications for personal or family history of medullary thyroid carcinoma): whether sub-therapeutic doses produce the same signal is unknown
• Cardiovascular effects over decades of use
• Pancreatic effects at low-level chronic exposure

The Prescribing Grey Area

In the UK, GLP-1 medications are prescribed at licensed doses. A prescriber recommending or facilitating a sub-therapeutic dosing protocol is working outside standard practice. Most responsible clinicians will not do this without evidence, which creates a practical problem: women who want to explore microdosing may end up doing so outside clinical oversight entirely.

This is the riskiest version of microdosing, specifically because the monitoring, contraindication checking, and adjustment that clinical oversight provides is absent.

Suboptimal Weight Maintenance

If the dose is insufficient, weight regain will occur gradually. Because it's gradual, it can be rationalised away ("I've just been a bit more relaxed lately") rather than recognised as the medication failing to maintain its effect. By the time the regain is acknowledged, it may be substantial.

How to Approach This Sensibly

If you're considering microdosing after reaching your goal weight, here is the most sensible framework:

1. Raise it with your prescriber first. Some forward-thinking clinicians are open to discussing this, particularly as the clinical conversation around long-term GLP-1 maintenance evolves. It's worth asking before going off-script alone.

2. Have a monitoring plan. If you reduce your dose, weigh yourself weekly. Set a threshold, say, 3kg of regain, at which point you reassess. Don't let gradual regain go unacknowledged.

3. Strengthen the non-pharmacological foundations first. Resistance training, protein targets, sleep, and stress management all affect weight maintenance. If these are not solid, reducing your dose without these foundations means the medication is doing more of the work than it should be. The guide to preventing muscle loss on GLP-1 covers the resistance training and nutrition framework you need in place before reducing your dose.

4. Consider structured alternatives. The two alternatives to indefinite full-dose maintenance or unsupervised microdosing are structured discontinuation with robust lifestyle support, or intermittent use with defined re-treatment criteria. Neither has strong evidence either, but both are at least discussions you can have with a prescriber.

For information on what full clinical support during GLP-1 treatment looks like, see the best GLP-1 clinic UK guide.

The Honest Summary

The rationale is not crazy. The absence of trials doesn't mean it's dangerous. But it also means nobody can tell you, with evidence, that it will work for you or that it's safe at 5 years. Those are the honest limits of what we currently know.

For anyone considering long-term GLP-1 use in any form, it's worth having baseline metabolic data in place. The blood tests before starting GLP-1 guide covers what to test before and during treatment. For context on how GLP-1 medications compare across weight loss and diabetes indications, see GLP-1 for diabetes vs weight loss.